TrialInvestigational new drugs2019
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer.
Haris Zahoor et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this papercites it